India’s pharmaceutical industry has achieved a historic milestone, with export revenues crossing ₹2 lakh crore (approximately USD 24 billion) in the fiscal year 2025-26, according to data from the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL).
Key Export Markets
The United States remains India’s largest pharmaceutical export market, accounting for 31% of total exports, followed by the European Union (17%), Africa (11%), and the UK (5%). Emerging markets in Southeast Asia and Latin America are showing the fastest growth rates.
Therapeutic Categories Leading Growth
- Oncology generics: +34% YoY growth
- Diabetes medications: +28% YoY growth
- Cardiovascular drugs: +22% YoY growth
- Biosimilars: +45% YoY growth (highest growth segment)
Challenges & Opportunities
While the milestone represents tremendous growth, the industry faces increasing scrutiny from US FDA and EMA regarding manufacturing quality standards. Several Indian facilities received warning letters in 2025, highlighting the need for sustained quality investment.
The Indian government’s Production Linked Incentive (PLI) scheme for pharmaceuticals has catalyzed significant capacity expansion, particularly in API (Active Pharmaceutical Ingredient) manufacturing, reducing dependence on Chinese API imports from 68% to 52%.
Pharmalix Market Analysis
Our latest India Pharma Market Report (2026) provides detailed analysis of export trends, top exporters, and growth opportunities. Access the full report here.
Leave a Reply